HSBC Holdings
LYEL icon

HSBC Holdings’s Lyell Immunopharma LYEL Stock Holding History

HSBC Holdings’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-936
Closed -$9.67K – 3150
2025
Q1 		$9.67K Sell
936
-6
-0.6% -$74 ﹤0.01% 2986
2024
Q4 		$11.9K Buy
942
+361
+62% +$7.16K ﹤0.01% 3066
2024
Q3 		$16.3K Sell
581
-335
-37% -$9.84K ﹤0.01% 2952
2024
Q2 		$25.3K Buy
916
+20
+2% +$952 ﹤0.01% 2863
2024
Q1 		$40K Buy
+896
New +$38.4K ﹤0.01% 2952

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return